Roche responds to the 'Herceptin or deception' article [1]

New Zealand Medical Journal

Volumn 119, Issue 1237, 2006, Pages

  Petersen, Svend ^a  

^a Roche Diagnostics New Zealand Ltd   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG INDICATION; EVIDENCE BASED MEDICINE; FUNDING; HUMAN; LETTER; METASTASIS; NEW ZEALAND; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION;

EID: 33746333885     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Final Appraisal Determination - Trastuzumab for the adjuvant treatment of early breast cancer. London: National Institute for Health and Clinical Excellence (NICE); 2006. Available online. URL: http:// www.nice.org.uk/page.aspx?o=328476 Accessed July 2006.
2. Herceptin (trastuzumab) Data Sheet. 15 March 2006. Roche Products (New Zealand) Ltd. 8 Henderson Place, Auckland.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72. Available online. URL: http://content.nejm.org/cgi/ content/full/353/16/1659 Accessed July 2006.
4. Slamon D, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Abstract presented at San Antonio Breast Cancer Symposium 8-11 December 2005.
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353:1673-84. Available online. URL: http://content.nejm.org/cgi/ content/full/353/16/1673 Accessed July 2006.
6. National Health Service. TA34 Breast cancer - trastuzumab: Guidance. London: National Institute for Clinical Excellence (NICE); 2002. Available online. URL: http://www.nice.org.uk/page.aspx?o=29280 Accessed July 2006.
7. Smith IE, et al. Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA trial): disease-free and overall survival after 2 year median follow-up. Scientific Special Session, American Society of Clinical Oncology (ASCO) Annual Meeting 2006.
8. Butler JRG, Furnival CM, Hart RFG. The costs of treating breast cancer in Australia and the implications for breast cancer screening. Australian and New Zealand Journal of Surgery. 1995;65:485-91.
9. Hurley SF, Huggins RM, Snyder RD, et al. The cost of breast cancer recurrences. British Journal of Cancer. 1992;65:449-55.
10. Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2 positive women: a single technology appraisal. School of Health and Related Research (ScHARR); May 2006. Available online. URL: http://www.nice.org.uk/page.aspx?o=282270 Accessed July 2006.